TENX
SHORT CANDIDATEMeanRevComposite
19.40
Technical
1.30
Fundamental
25.50
Rank
—
Price
1.83
Hurst
0.23
As of
Sep 16, 2026
Daily
Tenax Therapeutics, Inc.
HealthcareBiotechnologyTenax Therapeutics is a pharmaceutical development company focused on cardiopulmonary treatments. The company is advancing multiple drug candidates including TNX-101, TNX-102, and TNX-103 (levosimendan) for pulmonary hypertension associated with heart failure, along with TNX-201 (imatinib), a tyrosine kinase inhibitor being developed for chronic myeloid leukemia. Headquartered in Chapel Hill, North Carolina, the company was established in 1967 and operates primarily in the United States.
Market cap
$69.6M
P/E (trailing)
—
P/E (forward)
-1.24
PEG ratio
1.44
Dividend yield
—
Beta
0.82
52w range
1.31 – 19.40
Return on equity
-59.80%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 1.86 (-71.0%) · range 1.38–18.32
Cycle position
0/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 80 · STRONG SETUP · exit proximity 0
Conviction
43/ 100 · maturity 43%
VScore.2218
Buildup.2631
EMA entry setup.3280
Fundamentals.1926
Volume profile
POC
1.85
Price vs POC
+0.4%
Overhead supply
57%
Runway
open sky
Value area 1.31–2.40 · 57% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| insider-activity | 0.408 | Sep 16, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -4.62% | -4.62% | 1/20d |
| 40d | -4.62% | -4.62% | 1/40d |